HAYWARD, Calif., Sept. 29, 1999 (PRIMEZONE) - RiboGene, Inc. (AMEX:RBO) shares have recently been recommended in an analyst report just released by WallStreet Research, a prominent research boutique led by Alan stone Managing director of Alan Stone & Company, LLC and Joseph E. Jones, CFA, a former Director of Research at the American Stock Exchange. Mr. Jones, earlier in his career, was a senior analyst at Brown Brothers, Harriman & Co. and Standard & Poor's. Mr. Stone was formerly an analyst and assistant portfolio manager at Merrill Lynch Asset Management and securities analyst at Prudential Insurance Company's Capital Markets Group.
RiboGene, Inc., founded in 1989 and based in Hayward, Calif., is a rapidly growing pharmaceutical and drug discovery company. The Company's research and development efforts are focused on developing novel therapeutics for treatment of infectious diseases by using a drug discovery system based on transnational control of gene expression. Through a recent merger agreement with Cypros Pharmaceutical Corporation (AMEX:CYP), the Company secured three approved and marketed acute care products for marketing, expanded and diversified its late-stage-development product portfolio, as well as research efforts in the cytoprotective area. Trading on the AMEX under the symbol RBO since its IPO in May 1998, RoboGene is emerging as a fully integrated specialty pharmaceutical marketing and product development organization.
WallStreet Research specializes in the microcap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. The report can also be visited together with additional information about WallStreet Research at www.Wallst-Research.com.
Statements in this release that are not strictly historical and are "forward-looking statements" and subject to risk and uncertainty. Factors that effect actual events or results materially include, but are not limited to: (I) the Company's ability to obtain subsequent financing to further its current and future business strategies, (ii) the Company's ability to attract and retain key technical employees; (iii) the Company's success against competitive products and services; (iv) the effects of business, economic, and market conditions; and (v) factors that influence the supply/demand for the Company's publicly traded common stock generally. The risk factors and other information contained in the Company's audited financial statements and other public disclosure documents should be considered in evaluating the company's prospects and future financial performance.
For more information on RiboGene, Inc. please visit company's website at www.ribogene.com, or please view the copy of the WallStreet Research report at www.ipomonitor.com/wsr or www.Wallst-Research.com.